These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38894542)

  • 1. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
    Cortese M; Torchiaro E; D'Andrea A; Petti C; Invrea F; Franco L; Donini C; Leuci V; Leto SM; Vurchio V; Cottino F; Isella C; Arena S; Vigna E; Bertotti A; Trusolino L; Sangiolo D; Medico E
    Mol Ther; 2024 Aug; 32(8):2741-2761. PubMed ID: 38894542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.
    Li X; Zhao L; Li W; Gao P; Zhang N
    Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
    Hyrenius-Wittsten A; Su Y; Park M; Garcia JM; Alavi J; Perry N; Montgomery G; Liu B; Roybal KT
    Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of non-genetically modified, CAR-like, NK cells.
    Coënon L; Rigal E; Courot H; Multrier C; Zemiti S; Lambour J; Pugnière M; de Toledo M; Bossis G; Cartron G; Robert B; Martineau P; Fauvel B; Presumey J; Villalba M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.
    Xu J; Meng Q; Sun H; Zhang X; Yun J; Li B; Wu S; Li X; Yang H; Zhu H; Aschner M; Relucenti M; Familiari G; Chen R
    Cell Death Dis; 2021 Nov; 12(12):1109. PubMed ID: 34839348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
    Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
    J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 16. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer.
    Wu X; Huang S
    Bull Cancer; 2019 Nov; 106(11):946-958. PubMed ID: 31711572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
    Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3176-3190. PubMed ID: 38722382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.
    Lopez E; Hidalgo S; Roa E; Gómez J; Hermansen Truan C; Sanders E; Carrasco C; Pacheco R; Salazar-Onfray F; Varas-Godoy M; Borgna V; Lladser A
    Oncoimmunology; 2023; 12(1):2225291. PubMed ID: 37363103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.